Iovance Biotherapeutics (NASDAQ: IOVA)
Iovance Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Iovance Biotherapeutics Company Info
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News & Analysis
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth.
Why Iovance Biotherapeutics Stock Plummeted Today
The company's top line nearly doubled.
Iovance (IOVA) Q2 Revenue Jumps 93%
Is Iovance Biotherapeutics Stock Due for a Big Rally?
The biotech stock has been picking up steam of late -- but will it last?
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
Even the average price estimate for this stock suggests it can soar, but not everyone's convinced.
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside
Is This Beaten-Down Stock a Millionaire Maker?
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
Valuation
Earnings Transcripts
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2021.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
IOVA earnings call for the period ending March 31, 2020.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call Transcript
IOVA earnings call for the period ending December 31, 2019.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2019 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.